The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I study of LY3410738, a first-in-class covalent inhibitor of mutant IDH1 in cholangiocarcinoma and other advanced solid tumors.
 
James Michael Pauff
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
Travel, Accommodations, Expenses - Abbvie
 
Kyriakos P. Papadopoulos
Consulting or Advisory Role - ArQule; Basilea; Bayer
Research Funding - 3D Medicines (Inst); Abbvie (Inst); ADC Therapeutics (Inst); Amgen (Inst); Anheart Therapeutics (Inst); ARMO BioSciences (Inst); ArQule (Inst); Bayer (Inst); Calithera Biosciences (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); F-star (Inst); Incyte (Inst); Jounce Therapeutics (Inst); Linnaeus Therapeutics (Inst); MabSpace Biosciences (Inst); MedImmune (Inst); Merck (Inst); Mersana (Inst); Mirati Therapeutics (Inst); OncoMed (Inst); Peloton Therapeutics (Inst); Regeneron (Inst); Sanofi (Inst); Syros Pharmaceuticals (Inst); Tempest Therapeutics (Inst)
 
Filip Janku
Stock and Other Ownership Interests - Trovagene
Consulting or Advisory Role - Deciphera; Foundation Medicine; Guardant Health; IDEAYA Biosciences; IFM Therapeutics; Immunome; Jazz Pharmaceuticals; Novartis; PureTech; Sequenom; Sotio; Synlogic; Trovagene; Valeant/Dendreon
Research Funding - Agios (Inst); Asana Biosciences (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); BioMed Valley Discoveries (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Deciphera (Inst); Fujifilm (Inst); Genentech (Inst); Novartis (Inst); Piqur (Inst); Plexxikon (Inst); Proximagen (Inst); Roche (Inst); Symphogen (Inst)
Other Relationship - Bio-Rad
 
Anita Ahmed Turk
Research Funding - Lilly (Inst)
 
Lipika Goyal
Consulting or Advisory Role - Agios; Alentis Therapeutics; AstraZeneca; Debiopharm Group; H3 Biomedicine; Incyte; Klus Pharma; QED Therapeutics; Sirtex Medical; Taiho Pharmaceutical
(OPTIONAL) Uncompensated Relationships - Agios; Debiopharm Group; Taiho Pharmaceutical
 
Rachna T. Shroff
Consulting or Advisory Role - Agios; AstraZeneca; Boehringer Ingelheim; Clovis Oncology; Debiopharm Group; Exelixis; Incyte; Merck; QED Therapeutics; Seagen; Taiho Pharmaceutical
Research Funding - Agios; Exelixis; Halozyme; Merck; Pieris Pharmaceuticals; QED Therapeutics; Rafael Pharmaceuticals; Taiho Pharmaceutical
 
Toshio Shimizu
Honoraria - Boehringer Ingelheim; Chugai Pharma; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - Takeda
Speakers' Bureau - Boehringer Ingelheim; Chugai Pharma; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - 3D Medicines (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Chordia Therapeutics (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Five Prime Therapeutics (Inst); Incyte (Inst); Lilly (Inst); Novartis (Inst); PharmaMar (Inst); SymBio Pharmaceuticals (Inst); Takeda/Millennium (Inst)
Travel, Accommodations, Expenses - Takeda
 
Masafumi Ikeda
Honoraria - Astellas Pharma; AstraZeneca; Bayer Yakuhin; Chugai Pharma; Dainippon Sumitomo Pharma; EA Pharma; Eisai; Gilead Sciences; Kaken Pharmaceutical; Lilly Japan; MSD; Mylan; Novartis; Otsuka; SERVIER; Taiho Pharmaceutical; Takeda; Teijin Pharma; Yakult Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; Eisai; Lilly Japan; Micron; Novartis; Ono Pharmaceutical; SERVIER; Shire; Takeda; Teijin Pharma
Research Funding - ASLAN Pharmaceuticals (Inst); AstraZeneca (Inst); Bayer Yakuhin (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Eisai (Inst); J-Pharma (Inst); Lilly Japan (Inst); Merck (Inst); Merck Serono (Inst); MSD (Inst); NanoCarrier (Inst); Nobelpharma (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Takeda (Inst); Yakult Pharmaceutical (Inst)
 
Nilofer Saba Azad
Honoraria - AMAG Pharmaceuticals; QED Therapeutics
Consulting or Advisory Role - AMAG Pharmaceuticals; Dava Oncology; QED Therapeutics; Taiho Pharmaceutical
Research Funding - Agios (Inst); Array BioPharma (Inst); Astex Pharmaceuticals (Inst); Bayer; Bristol-Myers Squibb (Inst); Celgene (Inst); Debiopharm Group; EMD Serono; Genentech (Inst); Incyte; Intensity Therapeutics (Inst); Merck (Inst); Syndax (Inst)
 
James M. Cleary
Consulting or Advisory Role - Bristol-Myers Squibb
Research Funding - Abbvie (Inst); AstraZeneca; Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Esperas Pharma; Merck; Merus (Inst); Roche/Genentech (Inst); Tesaro
Travel, Accommodations, Expenses - Agios; Bristol-Myers Squibb; Roche
 
Mary Linton Bounetheau Peters
Stock and Other Ownership Interests - Abbott Laboratories (I); Amgen (I); Johnson & Johnson (I); Lilly; Lilly (I); Medtronic; Medtronic (I); Merck; Pfizer (I); Procter & Gamble
Honoraria - Bayer; Exelixis
Consulting or Advisory Role - Agios
Research Funding - Ambry Genetics (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Berg Pharma (Inst); Exelixis (Inst); Merck (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Exelixis; Halozyme
 
Mitesh J. Borad
Stock and Other Ownership Interests - AVEO; Gilead Sciences; Intercept Pharmaceuticals; Spectrum Pharmaceuticals
Consulting or Advisory Role - Agios (Inst); ArQule (Inst); Celgene (Inst); De Novo Pharmaceuticals; Exelixis; Fujifilm (Inst); G1 Therapeutics; Genentech; Halozyme (Inst); Immunovative Therapies; Imvax; Inspyr Therapeutics; Insys Therapeutics (Inst); Klus Pharma; Lynx Group; Merck; Novartis (Inst); Pieris Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); Western Oncolytics
Research Funding - Adaptimmune (Inst); Agios (Inst); ARIAD (Inst); Basilea (Inst); BiolineRx (Inst); Boston Biomedical (Inst); Celgene (Inst); Dicerna (Inst); Eisai (Inst); EMD Serono (Inst); Halozyme (Inst); ImClone Systems (Inst); Incyte (Inst); Incyte (Inst); Isis Pharmaceuticals (Inst); MedImmune (Inst); Merck Serono (Inst); miRNA Therapeutics (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); RedHill Biopharma (Inst); Senhwa Biosciences (Inst); Sillajen (Inst); Sun Biopharma (Inst); Taiho Pharmaceutical (Inst); Threshold Pharmaceuticals (Inst); Toray Industries (Inst)
Travel, Accommodations, Expenses - ArQule; AstraZeneca; Celgene
 
Kurt A. Jaeckle
Stock and Other Ownership Interests - Entegrion
 
Sani Haider Kizilbash
Research Funding - Apollomics (Inst); Celgene (Inst); DelMar Pharmaceuticals (Inst); Orbus Therapeutics (Inst); Wayshine Biopharma (Inst)
 
Rebecca Tupper
Employment - Lilly; Loxo
Stock and Other Ownership Interests - Lilly; Loxo
 
Carrie E. Furin
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Matthew P. Hanley
Employment - Aetna (I); Loxo
Stock and Other Ownership Interests - Loxo; Thetis Pharma
 
Elizabeth Goodwin Hill
Employment - Loxo
Stock and Other Ownership Interests - Lilly
 
Xiaojian Xu
Employment - Loxo
Stock and Other Ownership Interests - Lilly
 
James J. Harding
Consulting or Advisory Role - Adaptimmune; Bristol-Myers Squibb; CytomX Therapeutics; Eisai; Exelixis; Imvax; Lilly; Merck; Zymeworks
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Debiopharm Group (Inst); Incyte (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Polaris (Inst); Yiviva (Inst); Zymeworks (Inst)